CN111642736A - 一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 - Google Patents
一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 Download PDFInfo
- Publication number
- CN111642736A CN111642736A CN202010584976.3A CN202010584976A CN111642736A CN 111642736 A CN111642736 A CN 111642736A CN 202010584976 A CN202010584976 A CN 202010584976A CN 111642736 A CN111642736 A CN 111642736A
- Authority
- CN
- China
- Prior art keywords
- formula
- fatigue
- resisting
- environment
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000002929 anti-fatigue Effects 0.000 title claims description 7
- 230000002429 anti-coagulating effect Effects 0.000 title claims description 3
- 230000000694 effects Effects 0.000 claims abstract description 31
- 230000002028 premature Effects 0.000 claims abstract description 12
- 230000006870 function Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 15
- 241000237921 Urechis unicinctus Species 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 241000414067 Inonotus obliquus Species 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 241000208340 Araliaceae Species 0.000 claims description 10
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 10
- 241000723298 Dicentrarchus labrax Species 0.000 claims description 10
- 240000000759 Lepidium meyenii Species 0.000 claims description 10
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 235000017803 cinnamon Nutrition 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 9
- 210000003056 antler Anatomy 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 230000015271 coagulation Effects 0.000 claims description 6
- 238000005345 coagulation Methods 0.000 claims description 6
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 5
- 240000006108 Allium ampeloprasum Species 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 241000283007 Cervus nippon Species 0.000 claims description 5
- 241000237502 Ostreidae Species 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 239000004570 mortar (masonry) Substances 0.000 claims description 5
- 235000020636 oyster Nutrition 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 230000010100 anticoagulation Effects 0.000 abstract description 5
- 230000004089 microcirculation Effects 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 150000003904 phospholipids Chemical class 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 235000019155 vitamin A Nutrition 0.000 abstract 1
- 239000011719 vitamin A Substances 0.000 abstract 1
- 229940045997 vitamin a Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 230000009182 swimming Effects 0.000 description 11
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 10
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 10
- 239000003114 blood coagulation factor Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229920002527 Glycogen Polymers 0.000 description 8
- 230000009194 climbing Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940096919 glycogen Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 6
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 6
- 229940019700 blood coagulation factors Drugs 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 235000018645 Allium odorum Nutrition 0.000 description 4
- 244000003377 Allium tuberosum Species 0.000 description 4
- 235000005338 Allium tuberosum Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000006538 anaerobic glycolysis Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 101100224484 Mus musculus Pole gene Proteins 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- -1 ammonia ions Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960002223 arginine aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/20—Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/50—Molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/70—Comminuted, e.g. emulsified, fish products; Processed products therefrom such as pastes, reformed or compressed products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/655—Aquatic animals other than those covered by groups A61K35/57 - A61K35/65
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oceanography (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Abstract
本发明公开了一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法,其成分为海鲈鱼鱼白、单环刺螠、去壳牡蛎、鹿茸血、桦树茸、人参、黄精、肉桂、玛咖、韭菜籽。本组方富含蛋白质、维生素A、B族维生素、钙、镁、锌、硒,磷脂、矿物质、胶原蛋白、蛋白聚糖、透明质酸、核苷酸、神经节苷脂、生长激素及多种人体必须的氨基酸,能够促进血液循环,及时清除血管内垃圾,达到抗疲劳、抗早衰,抗凝、抗血栓的效果,确保微循环畅通,有效预防“未老先衰”。
Description
技术领域:
本发明属于保健食品领域,特别是涉及一种具有抗疲劳、抗早衰及抗凝血功效药食同源的组方及其制备方法。
背景技术:
随着社会的快速发展,生活节奏的加快以及社会竞争的加剧,人们心理压力和生理压力也随之加大。很多人因此而出现了易疲劳、早衰和免疫力下降等亚健康的症状。导致亚健康的主要表象原因有:饮食不合理、缺乏运动、作息不规律、睡眠不足、精神紧张、心理压力大以及长期不良情绪等。
其实疲劳是机体常见的生理现象,在脑力或体力活动达到一定阶段出现的生理现象,使工作效率下降。中医认为疲劳是机体内的精气、血、津液的缺失产生,针对这一原因中医通过辨证组方调治来治疗疲劳。经典方剂“梅花鹿鞭膏”具有缓解体力疲劳的功效。为了更加复合现代人的疲劳病因,我们实施了科学的配伍研究,在传统方剂的基础上,辨证加减,并科学添加最新发现的天然产物食材,使其更安全、更有效,且复合现代人的生理和心理特点。同时,最新的科学研究发现,影响系统衰老速度的根本原因在于微循环的瘀、堵程度和速度。也就是说,人的衰老和寿命取决于微循环。因此,促进血液循环,及时清除血管内垃圾,抗凝、抗血栓形成,确保微循环畅通,是有效预防“未老先衰”的医学基础和关键所在。
为解决以上问题,在参考传统典籍,结合现代医药领域的最新科技成果的基础上,经长期潜心研究和实践验证,发明了本组方。
发明内容:
本发明的目的在于提供一种具有抗疲劳、抗早衰及抗凝血功效的组方,能够促进血液循环,及时清除血管内垃圾,达到抗凝、抗血栓的效果,确保微循环畅通,有效预防“未老先衰”。
本发明的另一目的在于提供一种具有抗疲劳、抗早衰及抗凝血功效组方的制备方法,该方法能最大程度保留天然食材中的有效成分,且操作简单、便捷。
为了达成上述目的,本发明的技术方案是:
本发明组方是由以下重量份的原料组成:海鲈鱼鱼白500-2000g、单环刺螠500-2000g、去壳牡蛎200-1000g、鹿茸血100-500g、桦树茸200-800g、人参200-800g、黄精200-800g、肉桂100-500g、玛咖100-500g、韭菜籽100-500g。其中海鲈鱼鱼白、单环刺螠来源于野生海域环境(非人工养殖)、鹿茸血源自东北梅花鹿,桦树茸来源于俄罗斯境内的原始森林。
本组方中海鲈鱼鱼白是鱼类的精巢,鱼制造和储存精子的器官就是鱼白,鱼白中含有很高的营养价值,鱼白含有一种特殊的蛋白质,叫鱼精蛋白,是自然界中最简单的一种碱性蛋白质,鱼精蛋白可与胰岛素、抗菌素、肾上腺皮质激素等药物形成混合物,以延长这些药物的疗效;鱼类精巢中含有大量脱氧核糖核酸(DNA),可以用于治疗因使用抗癌药或放射疗法治疗引起的白细胞减少症,也可用于治疗再生障碍性贫血、血小板减少、肝炎、牛皮癣等疾病;鱼精巢的提取物精氨酸是治疗肝昏迷的特效药物;人体内如精氨酸含量不足,就会影响人体的生物代谢速度,用精氨酸为原料制成的精氨酸门冬酸酯,可以治疗疲劳、睡眠不足和记忆障碍;《中国药典》中记载,鹿茸为鹿科动物梅花鹿或马鹿的雄鹿未骨化密生茸毛的幼角,具有壮肾阳、益精血、强筋骨、调冲任、托疮毒的功效,用于肾阳不足、精血亏虚、阳痿滑精、宫冷不孕、羸瘦、神疲、畏寒、眩晕、耳鸣、耳聋、腰脊冷痛、筋骨痿软、崩漏带下、阴疽不敛,现代药理学表明,鹿茸具有抗应激、缓解骨质疏松、减肥降脂、抗氧化和抗衰老、抗疲劳、抗肿瘤等功效,可调节生殖系统、免疫系统、心血管系统、神经系统等,鹿茸中主要含有氨基酸、脂类、多肽、多糖、多胺、无机元素、蛋白质、激素样物质、生物碱基等化学成分;桦树茸有一定的降低胆固醇,调节血压的作用,桦树茸也可以消除氧自由基,保护细胞,提高机体清除自由基,增加细胞寿命,促进代谢,起到抗氧化的作用,还能够抑制癌细胞增加繁殖,影响肿瘤细胞周期,进而起到抗癌的作用。其中,桦树茸中含有多糖类,三萜类等有效物质能活化免疫系统,抑制人类免疫缺陷病毒蛋白酶,它还具有稳固细胞壁的作用,阻碍病毒释放酶,阻止病毒在细胞壁上附着,抑制病毒的繁殖和复制;单环刺螠体壁肌中含有18种氨基酸,其中包括8种人体必需氨基酸,在这些必需氨基酸中,亮氨酸含量最高,其次为赖氨酸和缬氨酸,非必需氨基酸含量以甘氨酸最高,其次为谷氨酸、丙氨酸,被盛誉为“裸体海参”,研究表明,单环刺螠体内含有许多抗凝生物活性物质,可为开发海洋生物药品、保健品提供新资源;牡蛎味咸性微寒,归肝、胆、肾经,具有平肝潜阳,收敛固涩,软坚散结,镇惊安神的功效。牡蛎中含有大量蛋白质、糖原、维生素、氨基酸及生物活性肽、二十碳五烯酸、牛磺酸以及微量元素等,具有增强免疫、抗肿瘤、降血压、抗氧化等诸多功能;人参中含有丰富的蛋白、多糖及皂苷类物质。人参皂苷是人参中主要的活性物质,具有抗氧化、抗肿瘤、抗心肌缺血、抗衰老、改善记忆力等广谱的药理活性。人参皂苷Rg3可提高SOD活性,降低大鼠骨骼肌MDA的释放。人参皂苷抗疲劳的机制较为复杂,可能是通过促进机体有氧糖酵解,清除氧化自由基及乳酸堆积,保护线粒体功能,降低骨骼肌受损;黄精性平、味甘,入脾、肾、肺经,具有补肾益精、滋阴润燥的功效,长期用于治疗肾虚亏损、脾胃虚弱、肺虚燥咳,体倦乏力等。现代药理学认为,黄精具有降血糖、血脂,保护心血管系统、调节和增强免疫功能、延缓衰老、抗炎、抗病毒等诸多药理作用;肉桂属樟科常绿乔木。肉桂具有补火助阳,引火归元,散寒止痛,温通经脉的作用,临床常用于治疗阳痿、宫冷、腰膝冷痛、肾虚作喘、目赤咽痛、虚寒吐泻、阳虚眩晕、闭经、痛经等。现代药理活性研究表明肉桂具镇痛、抗菌、抗肿瘤、降血糖和降血压的作用;玛咖富含蛋白质和多种生物活性物质,经常食用有助于改善机体疲劳状态,增强免疫力和缺氧耐受力,提高机体抗氧化水平,延缓衰老以及防治前列腺增生等。玛咖富含抗疲劳相关的多种活性组分,对健康小鼠具有显著的抗疲劳功能,是开发抗疲劳功能食品的理想原料;韭菜籽有多种活性成分,主要含生物碱类、核苷类、甾体皂苷、挥发油类、不饱和脂肪酸类等,现代药理研究表明韭菜籽具有补肾壮阳、养肝、固精等作用。
一种具有抗疲劳、抗早衰及抗凝血组方的制备方式如下:
(1)取新鲜的海鲈鱼鱼白、单环刺螠、去壳牡蛎,沥干水分;然后混合,绞碎,加入新鲜鹿茸血,置于冻干盘中,厚度不高于5mm,覆一层保鲜膜置于-60℃冷阱中预冻3-5h,然后真空冷冻干燥36-48h,真空度小于15Pa,冻干至含水量低于10%,取出;在湿度低于20%环境中,用研钵研成粉末,过80目筛,密封,冰箱冷藏保存、备用;
(2)取桦树茸、人参、黄精、肉桂、玛咖、韭菜籽,6倍量水煎2次,毎次2h,合并两次提取液,浓缩至浸膏液,浓缩干燥至含水量小于7%,在湿度低于20%环境中,粉碎,过80目筛,备用;
(3)在湿度低于20%环境中,将以上(1)(2)步制备的两种粉末混合均匀,密封,冰箱冷藏保存;
(4)将(3)中混合后的粉末,用全自动胶囊机,按照制备胶囊工序,装入1号胶囊,经检验合格后装瓶。
具体实施方式:
以下的处方组成及用量为1000剂本方剂的组成和原材料用量。
实施例1:
(1)取新鲜的海鲈鱼鱼白750g、单环刺螠700g、去壳牡蛎200g,沥干水分;然后处理办法如下:混合,绞碎,加入新鲜鹿茸血200g,置于冻干盘中,厚度不高于5mm,覆一层保鲜膜置于-60℃冷阱中预冻4h,然后真空冷冻干燥45h,真空度小于15Pa,冻干至含水量低于10%,取出;在湿度低于20%环境中,用研钵研成粉末,过80目筛,密封,冰箱冷藏保存、备用;
(2)取桦树茸250g、人参(5年及5年以下人工种植)250g、黄精200g、肉桂150g、玛咖150g、韭菜籽150g,6倍量水煎2次,毎次2h,合并两次提取液,浓缩至浸膏液,浓缩干燥至含水量小于7%,在湿度低于20%环境中,粉碎,过80目筛,备用;
(3)在湿度低于20%环境中,将以上(1)(2)步制备的两种粉末混合均匀,密封,冰箱冷藏保存;
(4)将(3)中混合后的粉末,用全自动胶囊机,按照制备胶囊工序,装入1号胶囊,经检验合格后装瓶。
实施例2:
(1)取新鲜的海鲈鱼鱼白650g、单环刺螠650g、去壳牡蛎300g,沥干水分;然后处理办法如下:混合,绞碎,加入新鲜鹿茸血250g,置于冻干盘中,厚度不高于5mm,覆一层保鲜膜置于-60℃冷阱中预冻3-5h,然后真空冷冻干燥36-48h,真空度小于15Pa,冻干至含水量低于10%,取出;在湿度低于20%环境中,用研钵研成粉末,过80目筛,密封,冰箱冷藏保存、备用。
(2)取桦树茸300g、人参(5年及5年以下人工种植)250g、黄精200g、肉桂200g、玛咖100g、韭菜籽100g,6倍量水煎2次,毎次2h,合并两次提取液,浓缩至浸膏液,浓缩干燥至含水量小于7%,在湿度低于20%环境中,粉碎,过80目筛,备用。
(3)在湿度低于20%环境中,将以上(1)(2)步制备的两种粉末混合均匀,密封,冰箱冷藏保存。
(4)将(3)中混合后的粉末,用全自动胶囊机,按照制备胶囊工序,装入1号胶囊,经检验合格后装瓶。
实施例3:
(1)取新鲜的海鲈鱼鱼白500g、单环刺螠500g、去壳牡蛎200g,沥干水分;然后处理办法如下:混合,绞碎,加入新鲜鹿茸血100g,置于冻干盘中,厚度不高于5mm,覆一层保鲜膜置于-60℃冷阱中预冻3-5h,然后真空冷冻干燥36-48h,真空度小于15Pa,冻干至含水量低于10%,取出;在湿度低于20%环境中,用研钵研成粉末,过80目筛,密封,冰箱冷藏保存、备用。
(2)取桦树茸350g、人参(5年及5年以下人工种植)350、黄精300g、肉桂250g、玛咖250g、韭菜籽200g,6倍量水煎2次,毎次2h,合并两次提取液,浓缩至浸膏液,浓缩干燥至含水量小于7%,在湿度低于20%环境中,粉碎,过80目筛,备用。
(3)在湿度低于20%环境中,将以上(1)(2)步制备的两种粉末混合均匀,密封,冰箱冷藏保存。
(4)将(3)中混合后的粉末,用全自动胶囊机,按照制备胶囊工序,装入1号胶囊,经检验合格后装瓶。
一、抗疲劳的效果考察:
依据实施例处方进行缓解体力疲劳功效研究,实验小鼠在适应1周后,试验设3个剂量组(实施例1组、实施例2组、实施例3组)、1个阳性组(梅花鹿鞭膏组,吉林益衡生态产品科技有限公司生产)和1个空白对照组,空白对照组用水灌胃,阳性组给药剂量均为0.5g/kg,实验组分别给予实施例1、2、3处方制作的本品,给药剂量为0.8g生药量/kg(相当于人体推荐用量的5倍),每只小鼠灌胃体积为0.4mL/20g,每天灌胃1次,连续灌胃2周后,小鼠进行负重游泳、爬杆实验以及疲劳相关指标测定。
(1)小鼠负重游泳实验:
末次给予小鼠受试物1h后,置于游泳箱中游泳,水深约30cm,水温(25士0.5)℃,小鼠尾根部负荷5.0%质量的铅皮,记录小鼠自游泳开始至死亡的时间,作为小鼠负重游泳时间。
(2)小鼠爬杆实验:
末次给予小鼠受试物1h后,令小鼠抓握爬杆架的有机玻璃棒(垂直悬挂的光滑玻璃棒,长100cm,直径0.7cm),记录小鼠由于肌肉疲劳从有机玻璃棒上跌落的时间,第3次跌落时终止实验,累计3次的时间作为爬杆时间。
(3)统计方法
实验数据均采用SPSS15.0软件进行方差分析及组间i检验,P<0.05为差异有显著性。
(4)结果:
如表1所示,阳性对照组以及本组方实施例组的小鼠游泳时间、爬杆时间均长于空白组,本组方实施例组与空白组相比有显著性差异(P<0.05,P<0.01),本组方实施例1、2组的游泳时间以及爬杆时间长于阳性对照组,因此本组方的抗疲劳效果优于梅花鹿鞭膏(吉林益衡生态产品科技有限公司生产)组。
表1本组方对小鼠负重游泳时间、爬杆时间的影响(x±s,n=10)
注:与空白组比较*P<0.05,**P<0.01
二、疲劳相关生理指标测定
(1)肝脏组织采集及组织中糖原测定
末次给予小鼠受试物30min后,立即将小鼠颈椎脱臼处死,取出肝脏置于冰生理盐水中,剔除结缔组织,滤纸吸干,按糖原测试盒说明书操作,测定吸光度,计算肝糖原含量。
(2)血清采集及血清中BUN、LD、ATP、SOD
末次给予小鼠受试物30min后,在温度为(25±0.5)℃的水中不负重游泳30min,取出小鼠擦干后,心脏采血0.8mL,放于4℃静置过夜后,于4000r/min离心5min,分离血清,-20℃保存,按照各试剂盒测定方法测定血清中BUN、LD、ATP、SOD含量。
(3)统计方法
实验数据均采用SPSS15.0软件进行方差分析及组间i检验,P<0.05为差异有显著性。
(4)结果:
实验证实在同等运动强度下,本组方实施例1、2、3组均可降低小鼠血液中BUN、LD的含量,与空白对照组相比,实施例1、2、3组的BUN含量均明显下降,且实施例1、2组具有极显著差异(P<0.01),实施例3组有显著性差异(P<0.05),说明本组方可以明显降低剧烈运动后小鼠的血清尿素氮水平。实施例1、2、3组LD含量均比空白组及阳性组小,并且具有显著性差异(P<0.05)。与空白组相比,游泳后实施例组ATP含量高于空白组,其中实施例1组有显著性差异(P<0.01)。实施例组的SOD和肝糖原相对于空白组,含量明显升高,其中实施例1组较空白组有显著性差异(P<0.01)。
表2本组方对小鼠血液中BUN、LD、ATP、SOD和肝糖原的影响
注:与空白组比较*P<0.05,#P<0.01
实验结果表明本组方可显著提高爬杆时间、负重游泳时间,提高小鼠体内肝糖原、ATP以及SOD含量,说明本组方可降低因运动消耗体内糖原以及ATP供能,机体抗疲劳能力增强;SOD可消除机体在运动中产生的有害物质,SOD含量提高可说明本组方服用使产生的有害物质减少,延缓机体疲劳产生,增强机体抗疲劳能力。本组方还可明显降低BUN、LD含量,BUN为蛋白质分解代谢产物,当机体运动时机体能量供应不足会加快蛋白质代谢分解产生BUN,服用本组方后,降低了BUN含量,说明本组方可降低蛋白质代谢分解去维持机体能量代谢;LD是机体内无氧酵解功能体系的终产物,机体运动后有氧呼吸无法提供足够能量维持机体,机体会通过无氧酵解提供能量,使LD增加后导致肌肉中氨离子浓度上升,pH下降,引起机体生理生化变化,最终导致疲劳,本组方能降低蛋白质分解提供能量,减少无氧酵解产生LD,明显缓解体カ疲劳程度。
三、本组方对AT-III及HC-II抑酶作用的影响
(1)分别将标准血浆、乏AT-III和乏HC-II血浆冻干粉用双蒸水溶解,置于含有3.8%枸橼酸钠抗凝剂的离心管中,颠倒混匀后于24℃、3500r/min离心15min,收集上层液作为阳性对照组,以生理盐水为阴性对照组。分别向上层液中以1∶10加入4mg/mL本组方混悬液作为实验组,每组6个平行样本。各取0.2mL经37℃预温5min后分别向其中加入0.2mL预温15min的PT和TT试剂,全自动凝血仪测定并记录PT、TT凝血时间。
(2)实验数据均采用SPSS15.0软件进行方差分析及组间i检验,P<0.05为差异有显著性。
(3)本组方影响AT-III及HC-II抑制凝血酶活性结果
标准血浆、乏AT-III及乏HC-II血浆中加入本组方后的抗凝血酶作用结果如表3,与各组血浆对照组相比,加入本组方后的凝血时间与对照组相比,均有明显增加。
注:与标准血浆比较,*表示差异显著(p<0.05),**表示差异极显著(p<0.01);与乏AT III血浆比较,##表示差异极显著(p<0.01);与乏HC II血浆比较,bb表示差异极显著(p<0.01)
四、本组方对血浆凝血因子活性的影响
(1)以70μg/mL肝素钠为阳性对照组,生理盐水为阴性对照组,70μg/mL本组方混悬液为实验组,通过凝血因子测定试剂盒测定本组方对血浆凝血因子活性的影响。
(2)实验数据均采用SPSS15.0软件进行方差分析及组间i检验,P<0.05为差异有显著性。
(3)本组方影响凝血因子活性结果
本组方对血浆凝血因子活性的影响结果如表4所示,本组方对血浆纤维蛋白原(FIB)含量的影响与对照组相比无明显差异,肝素钠组FIB含量低于对照组,未达显著水平;与对照组相比,肝素钠、本组方均能够极显著降低各凝血因子活性(p<0.01);与肝素钠组相比,本组方对凝血因子II影响差异极显著(p<0.01),对因子VII、VIII、XI影响差异显著(p<0.05)。
注:与对照组比较,*表示差异显著(p<0.05),**表示差异极显著(p<0.01);与肝素钠组比较,#表示差异极显著(p<0.05),##表示差异极显著(p<0.01)
凝血酶通过激活凝血因子V和X并在磷脂胶粒、Ca2+作用下发挥作用,本实验选择凝血因子II、V、VII、X及AT-III及HC-II为研究对象,进一步研究本组方对凝血因子活性的影响,由实验结果可得本组方对抗凝机制的影响有较为显著;本组方可同时作用于内、外源性凝血途径,多位点抑制凝血酶的形成,从而防止体内血栓的形成,有效实现抗机体早衰的效果。
Claims (3)
1.一种具有抗疲劳、抗早衰及抗凝血的组方,其特征在于,含有以下组分:海鲈鱼鱼白、单环刺螠、去壳牡蛎、鹿茸血、桦树茸、人参、黄精、肉桂、玛咖、韭菜籽。
2.根据权利要求1所述的一种具有抗疲劳、抗早衰及抗凝血的组方,其特征在于,含有以下重量份的原料:海鲈鱼鱼白500-2000g、单环刺螠500-2000g、去壳牡蛎200-1000g、鹿茸血100-500g、桦树茸200-800g、人参200-800g、黄精200-800g、肉桂100-500g、玛咖100-500g、韭菜籽100-500g,其中海鲈鱼鱼白、单环刺螠来源于野生海域环境(非人工养殖)、鹿茸血源自东北梅花鹿,桦树茸来源于俄罗斯境内的原始森林。
3.一种具有抗疲劳、抗早衰及抗凝血功效组方的制备方法,其特征在于:
(1)取新鲜的海鲈鱼鱼白、单环刺螠、去壳牡蛎,沥干水分,然后混合,绞碎,加入新鲜鹿茸血,置于冻干盘中,厚度不高于5mm,覆一层保鲜膜置于-60℃冷阱中预冻3-5h,然后真空冷冻干燥36-48h,真空度小于15Pa,冻干至含水量低于10%,取出;在湿度低于20%环境中,用研钵研成粉末,过80目筛,密封,冰箱冷藏保存、备用;
(2)取桦树茸、人参、黄精、肉桂、玛咖、韭菜籽,6倍量水煎2次,毎次2h,合并两次提取液,浓缩至浸膏液,浓缩干燥至含水量小于7%,在湿度低于20%环境中,粉碎,过80目筛,备用。
(3)在湿度低于20%环境中,将以上(1)(2)步制备的两种粉末混合均匀,密封,冰箱冷藏保存;
(4)将(3)中混合后的粉末,用全自动胶囊机,按照制备胶囊工序,装入1号胶囊,经检验合格后装瓶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010584976.3A CN111642736A (zh) | 2020-06-16 | 2020-06-16 | 一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010584976.3A CN111642736A (zh) | 2020-06-16 | 2020-06-16 | 一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111642736A true CN111642736A (zh) | 2020-09-11 |
Family
ID=72347477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010584976.3A Pending CN111642736A (zh) | 2020-06-16 | 2020-06-16 | 一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111642736A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406118A (zh) * | 2011-12-05 | 2012-04-11 | 哈尔滨怡康药业有限公司 | 一种韭白胶囊及其制备方法 |
CN104109705A (zh) * | 2014-06-19 | 2014-10-22 | 广东省农业科学院蚕业与农产品加工研究所 | 一种酶法制备具有促进伤口愈合活性的海洋胶原蛋白肽的方法 |
CN106690307A (zh) * | 2016-12-07 | 2017-05-24 | 珠海联邦制药股份有限公司 | 一种增强免疫力缓解体力疲劳的保健胶囊及其制备方法 |
CN107581619A (zh) * | 2017-09-11 | 2018-01-16 | 陈石良 | 一种抗疲劳抗衰老海参牡蛎肽复合胶囊及其制备方法 |
CN107752042A (zh) * | 2017-09-28 | 2018-03-06 | 赵德润 | 一种牡蛎活性肽的制备方法 |
CN109757637A (zh) * | 2018-02-11 | 2019-05-17 | 延边百草药材有限公司 | 含有桦树茸提取物的功能性饮料 |
WO2019235489A1 (ja) * | 2018-06-04 | 2019-12-12 | 株式会社明治 | 抗疲労組成物 |
CN111264862A (zh) * | 2020-02-10 | 2020-06-12 | 云南中科本草科技有限公司 | 一种抗疲劳组合物、其制备方法及抗疲劳药物或保健食品 |
-
2020
- 2020-06-16 CN CN202010584976.3A patent/CN111642736A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406118A (zh) * | 2011-12-05 | 2012-04-11 | 哈尔滨怡康药业有限公司 | 一种韭白胶囊及其制备方法 |
CN104109705A (zh) * | 2014-06-19 | 2014-10-22 | 广东省农业科学院蚕业与农产品加工研究所 | 一种酶法制备具有促进伤口愈合活性的海洋胶原蛋白肽的方法 |
CN106690307A (zh) * | 2016-12-07 | 2017-05-24 | 珠海联邦制药股份有限公司 | 一种增强免疫力缓解体力疲劳的保健胶囊及其制备方法 |
CN107581619A (zh) * | 2017-09-11 | 2018-01-16 | 陈石良 | 一种抗疲劳抗衰老海参牡蛎肽复合胶囊及其制备方法 |
CN107752042A (zh) * | 2017-09-28 | 2018-03-06 | 赵德润 | 一种牡蛎活性肽的制备方法 |
CN109757637A (zh) * | 2018-02-11 | 2019-05-17 | 延边百草药材有限公司 | 含有桦树茸提取物的功能性饮料 |
WO2019235489A1 (ja) * | 2018-06-04 | 2019-12-12 | 株式会社明治 | 抗疲労組成物 |
CN111264862A (zh) * | 2020-02-10 | 2020-06-12 | 云南中科本草科技有限公司 | 一种抗疲劳组合物、其制备方法及抗疲劳药物或保健食品 |
Non-Patent Citations (1)
Title |
---|
曹利丹: "桦褐孔菌多糖对小鼠抗运动疲劳的影响", 《赤峰学院学报(自然科学版)》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
KR20140126087A (ko) | 면역기능 및 항산화 물질을 항상 시키는 해조류와 곡물,한약류 와 혼합한 조성물. | |
CN102526698A (zh) | 虫草多肽氨基酸营养液 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
CN105901728A (zh) | 一种利于术后康复的组合物及其制备方法 | |
CN103610077A (zh) | 一种海参胶囊 | |
CN109123032A (zh) | 具有延年益寿温肾补阳温肾益阴功能的组合物与制备工艺 | |
WO2016141775A1 (zh) | 吉林人参低聚肽在制备抗疲劳的食品或保健食品中的用途 | |
CN107912773A (zh) | 一种用于缓解体力疲劳的制剂 | |
CN103082240B (zh) | 一种胡萝卜参的加工方法 | |
CN111642736A (zh) | 一种具有抗疲劳、抗早衰及抗凝血的组方及其制备方法 | |
CN109364117A (zh) | 一种抗疲劳的中药组合物 | |
CN108633997A (zh) | 一种具有抗疲劳功能的保健羊奶粉及其制备方法 | |
RU2332866C2 (ru) | Биологически активная добавка к пище "перстевит" | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
CN107087795A (zh) | 一种抗疲劳耐缺氧保健品组合物 | |
CN106165894A (zh) | 一种冲调即食型多种食用菌复合营养粉及其生产方法 | |
CN108355052B (zh) | 一种治疗放化疗后白细胞降低的药物及其制备方法与应用 | |
CN111000237A (zh) | 一种用于心脑血管病膳食干预的膳食组合物及制备方法 | |
CN109157548A (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
CN116370573B (zh) | 一种用于抗缺氧耐疲劳的中药及其制备方法 | |
CN106421028A (zh) | 一种抗运动性疲劳的中药组合物及其制备方法 | |
CN1695715A (zh) | 一种治疗血管性痴呆的药物及其制备方法 | |
CN108721407A (zh) | 一种气阳两虚体质调理足浴粉及其制备方法 | |
CN113100442B (zh) | 一种蜂王浆龟鳖肽嚼含片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200911 |
|
WD01 | Invention patent application deemed withdrawn after publication |